Enzo Biochem Long Term Debt 2010-2022 | ENZ

Enzo Biochem long term debt from 2010 to 2022. Long term debt can be defined as the sum of all long term debt fields.
Enzo Biochem Annual Long Term Debt
(Millions of US $)
2021 $4
2020 $4
2019 $4
2018 $
2017 $
2016 $
2015 $
2014 $
2013 $
2012 $
2011 $
2010 $
2009 $
Enzo Biochem Quarterly Long Term Debt
(Millions of US $)
2022-04-30 $4
2022-01-31 $4
2021-10-31 $4
2021-07-31 $4
2021-04-30 $4
2021-01-31 $4
2020-10-31 $4
2020-07-31 $4
2020-04-30 $5
2020-01-31 $4
2019-10-31 $4
2019-07-31 $4
2019-04-30 $4
2019-01-31 $4
2018-10-31
2018-07-31
2018-04-30
2018-01-31
2017-10-31
2017-07-31
2017-04-30
2017-01-31
2016-10-31
2016-07-31
2016-04-30
2016-01-31
2015-10-31
2015-07-31
2015-04-30
2015-01-31
2014-10-31
2014-07-31
2014-04-30
2014-01-31
2013-10-31
2013-07-31
2013-04-30
2013-01-31
2012-10-31
2012-07-31
2012-04-30
2012-01-31
2011-10-31
2011-07-31
2011-04-30
2011-01-31
2010-10-31
2010-07-31
2010-04-30
2010-01-31
2009-10-31
2009-07-31
2009-04-30
2009-01-31
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.133B $0.118B
Enzo Biochem, Inc. develops, manufactures and markets health care products based on molecular biology and genetic engineering techniques, and also provides diagnostic services to the medical community. The business activities of the company are performed by one of the company's three wholly-owned subsidiaries--Enzo Diagnostics, Inc., Enzo Therapeutics, Inc., and Enzo Clinical Labs, Inc. The primary focus of the company's research is the development of products based on two technology platforms -- genetic modulation and immune modulation.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $159.141B 9.65
GSK (GSK) United Kingdom $71.077B 8.53
Bio-Rad Laboratories (BIO.B) United States $15.412B 34.05
QIAGEN (QGEN) Netherlands $11.276B 18.88
Biohaven Pharmaceutical Holding (BHVN) United States $10.581B 0.00
Ginkgo Bioworks Holdings (DNA) United States $6.200B 0.00
Arcus Biosciences (RCUS) United States $2.020B 39.44
Myovant Sciences (MYOV) United Kingdom $1.765B 0.00
Emergent Biosolutions (EBS) United States $1.521B 8.81
Zymeworks (ZYME) Canada $0.418B 0.00
Gelesis Holdings (GLS) United States $0.101B 0.00
SQZ Biotechnologies (SQZ) United States $0.099B 0.00
Ambrx Biopharma (AMAM) United States $0.095B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.000B 0.00